Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Huzhou SilkFuture Bio-tech, also presented as Huzhou Xintiansi Bio-tech, is a China-based sericulture biotechnology and manufacturing company focused on silk- and silkworm-derived bioactive ingredients. The company develops, produces, and sells silk protein, silk amino acids, silk peptide, sericin powder, silk fibroin powder, silkworm chrysalis amino acids, and silkworm chrysalis protein powder, along with silk protein-based skin-friendly consumer products. Its business is centered on industrial-scale R&D and commercialization of sericulture resources rather than a drug-development pipeline. The company markets its materials into nutrition, food and beverage, cosmetics, fabrics, and personal care applications, and exports a large share of its products internationally. Based on available sources, it is better characterized as a commercial biomaterials and health ingredient supplier than as a therapeutics-focused biotech or pharma company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Huzhou Xintiansi Bio-tech.